October 17, 2026
Every successful investor knows a painful truth: knowing when to sell is often more critical than knowing what to buy.
While financial media overwhelmingly focuses on buying opportunities, our research consistently identifies companies facing significant headwinds that merit serious consideration for selling. These aren’t just stocks underperforming the market; they’re businesses confronting structural challenges, deteriorating fundamentals, or carrying valuations disconnected from financial reality.
What you won’t find here: reactionary calls based on short-term price movements or headline volatility. Each company on this list has been thoroughly analyzed across multiple metrics that historically precede substantial declines.
Smart investors understand that portfolio management requires both addition and subtraction. Sometimes the best investment decision is to redeploy capital away from troubling positions before problems fully materialize in the share price.
This week’s watchlist highlights stocks showing critical weaknesses that demand immediate attention:
FMC Corporation (FMC)
FMC demonstrates how a business can look like a bargain on paper right up until management admits the earnings base is collapsing. Shares fell roughly a third on Thursday after the agricultural chemicals company cut its third-quarter outlook far below what analysts had been modeling. Analysts polled by Yahoo! Finance had expected about $867 million in sales and $0.10 per share in profit, already a sharp earnings decline. Management now guides to revenue of only $65 million to $125 million and adjusted EBITDA of negative $510 million to $565 million. The company attributes the gap to $625 million to $675 million in price reductions on products held by channel customers, made necessary by weaker demand and rapid market price declines driven partly by generic competition.
The problem is structural rather than a one-quarter air pocket. FMC is cutting prices to clear old inventory, which may move product but does little for revenue or profit per unit. Generic competitors are compressing pricing across the industry, and the company’s earlier dividend cut, which reduced the quarterly payout by 92% last year, reflected the same pressure on cash flow. The 33.06% gross margin is a reminder of how thin the cushion becomes when selling prices fall faster than costs can follow. Shareholders who held through the earlier decline now face a business that is giving up margin to maintain volume.
Trading at around $6 per share, FMC has a market capitalization of roughly $880 million and a 52-week range of $4.85 to $30.95, meaning the stock has lost about 80% of its value over the past year. The lower price does not make the valuation cheap, because the earnings it is measured against are shrinking. Before the latest guidance, the stock traded at more than 30 times earnings, a multiple that now looks stretched against profits set to fall. For agricultural chemical investors, FMC is a case where cutting prices to fight competition may keep the lights on while leaving shareholders with little to show for it.
SSR Mining (SSRM)
SSR Mining has been one of the stronger performers in the precious metals group, with a 30.6% gain over the past year, but the stock is now losing some of its appeal. Shares fell on both Monday and Tuesday of the week, and were down about 8% in Wednesday trading after UBS trimmed its price target to $39 from $41. UBS kept a buy rating, but the new target implies only about 18% upside from the prior close, a much narrower margin than investors had been pricing in. For a stock that has already run, a smaller upside cushion leaves less room for error.
The valuation concern is the core of the argument. SSR Mining now trades at about 8.5 times operating cash flow, a premium to its five-year average of about 5.9 times. That gap matters because the company’s gold and silver production forecasts for 2026 are fixed within a range, and the upside from here depends on metal prices or on operating results beating those ranges. A premium multiple on a mining company is a bet that cash flow will keep rising, and when the analyst most positive on the name is cutting its target, the risk of that bet failing becomes harder to dismiss. The 48.92% gross margin is solid, but it does not change the arithmetic of paying more for each dollar of cash flow than the stock has historically commanded.
At around $32 per share and a market capitalization of about $6.5 billion, SSR Mining sits in the upper part of its 52-week range of $18.19 to $39.44. Its dividend yield of 0.09% offers almost no income support, so investors are relying entirely on price appreciation. The combination of a higher-than-usual valuation multiple, a shrinking analyst upside target and a recent pullback suggests the easy part of the rally is over. For precious metals investors, this is a stock whose valuation now assumes near-perfect execution.
Johnson & Johnson (JNJ)
Johnson & Johnson beat expectations and still lost ground, with shares falling about 7% at midday Tuesday. The company reported third-quarter adjusted earnings of $2.59 per share against analyst forecasts of $2.53 and sales that rose 5.9%, and it raised full-year guidance. But adjusted profit still fell 7.5%, and the headline GAAP figure collapsed to $0.09 per share, a 96% drop, after management booked a special charge tied to a proposed talc litigation resolution, the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines. Investors have seen this pattern before: large one-time charges that make adjusted figures look far healthier than the reported results underneath.
The underlying business is still generating cash, with free cash flow up more than 6% to $15.1 billion. Management now expects 2026 sales to grow 7.4% to $101.2 billion and adjusted earnings of about $11.10 per share. The problem is what that growth rate has to support. Litigation costs remain a live risk, and the company’s core growth at roughly 7% is modest for a stock valued this richly. A 74.91% gross margin protects profitability in good times, but it does not protect shareholders from paying a premium for mid-single-digit-type growth.
At around $256 per share and a market capitalization of approximately $616 billion, J&J trades at more than 22 times adjusted earnings and closer to 29 times free cash flow. The stock sits in the upper half of its 52-week range of $184.66 to $281.07, and the 2.07% dividend yield does little to offset a valuation that now prices in steady, not spectacular, growth. For healthcare investors, J&J looks like a company whose headline beat masks a weaker reported result, and whose valuation leaves little margin for litigation surprises or slower growth.
